💫🌟🔥 Hot off the press (Comments & Controversies)🌟💫 Thrilled to see the timely piece 👉 “Precision Oncology and Modernizing Evidence Standards” 🔑 Key takeaways: 🔵 RCT-only frameworks miss the reality of #PrecisionMedicine 🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology

🚨 NEJM | Sept 2025 Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA) “Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.” www.nejm.org/doi/full/10....

💫🌟🎓🆕Immune activation & ICI-related fatigue New study (JHU + Genentech) ✅ 58.5% of pts on ICIs reported fatigue ✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12) ✅ Expansion of CD8+ effector T cells ✅ Fatigue = surrogate of immune activation

🧓👵 Geriatric assessment vs clinical evaluation in MM J Geriatr Oncol (Sept 2025, Raddoux et al.) 👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients. 📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma

🧠 Neurotoxicity in Cancer Therapy New review (Nat Rev Clin Oncol) ✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity ✅ Clinical recognition & biomarkers ✅ Prevention & management strategies 🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025

📑 New ESMO CPG on Lymphomas ✅ Updated dx & staging recs ✅ 1L & r/r treatment algorithms ✅ Integration of CAR-T, bispecifics & BTKis www.annalsofoncology.org/article/S092...

🌟🟠 HER2 in mCRC New pooled analysis in JCO (8 RCTs, n=1,604)🌟 ✅ HER2+ = worse PFS & OS ❌ Not predictive for Bev vs anti-EGFR ➡️ Prognostic, not predictive #GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch ascopubs.org/doi/10.1200/...

🟢 Hepatocellular carcinoma (HCC) – 2025 global insights 🌍 New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.) 🔑 Highlights: ✅ 3rd leading cause of cancer death ✅ Etiology shift → viral ↓ | ALD & MASLD ↑ ✅ Prevention: HBV vax + antivirals effective

📢 European Journal of Cancer – New Research Cost-effectiveness of perioperative Durvalumab + Gem/Cis in MIBC (Germany) 📊 Results: ➡️ Cost: €113,224 (SoC) → €126,386 (+€13,162) ➡️ QALYs: 3.16 → 3.37 (+0.21) ➡️ ICER: €61,006/QALY ➡️ WTP €100,000 → 76.5% probability of cost-effectiveness

🌍 #MWGlobalOnc Prognosis & biology of ER-low metastatic breast cancer – TONIC & multicenter cohort 🔑 Key Messages: ✅ ER-low (1–9%) behaves biologically closer to TNBC than ER+/HER2− ✅ Worse OS vs ER+/HER2−; prognosis similar to TNBC ✅ Phenotypic switch from ER+ → ER-low at relapse = poor outcomes

✅ Barriers: resource gaps, training, access in LMICs ➡️ Clinical practice impact: GA should be mandatory in global oncology to optimize outcomes for older adults. #GeriatricOncology #ASCO #OncoTwitter #Medicalwatch #CancerCare #GlobalOncology ascopubs.org/doi/10.1200/...

Heading to an appointment this weekend? Plan ahead for street closures 🚧 👷 Aloha St. will be closed at Fairview Ave. N. from 7 p.m. Friday, 9/5 until 6 a.m. Monday, 9/8. This is part of the City of Seattle’s RapidRide J-Line construction project. bit.ly/47GyDV0

🎥 #MWVisualAbstract Surgical complexity after NACT in primary ovarian cancer ✍️ Chiara Ainio, Marina Rosanu, Lucia Ribero, Amanda L. Tapia, Giovanni D. Aletti, William A. Cliby et al. 🔶 Key Messages: ➡️ >50% of pts undergoing IDS after NACT required advanced procedures

💡 #MWClinicalTips FGFR1-amplified colorectal cancer: a distinct prognostic subtype ✅ Large-scale profiling (n=7606) → FGFR1 amplification = predominant FGFR alteration in CRC (≈4%). ✨ Independent marker of poor prognosis: ↓DFS (HR 2.91) & ↓PFS (HR 2.52).

#COTipTuesday 🔵 Prostate Cancer Statistics 2025 – CA Cancer J Clin ✅ 313,780 new cases & 35,770 deaths expected in US (2025) ✅ Incidence ↑ 3%/yr since 2014, driven by advanced-stage dx ✅ Distant-stage PCa rising across all ages 📈 ✅ Black men: 67% ↑ incidence & ~2x mortality vs White men

🟢 Circulating KIM-1 in adjuvant #RCC New Annals of Oncology analysis (IMmotion010): ✅ Elevated post-nephrectomy plasma KIM-1 = ↑ recurrence risk (HR 1.68) ✅ KIM-1high pts benefited from adjuvant atezo (HR 0.72)

🌟🫁 Early & locally advanced #NSCLC – New @myESMO Guidelines🌟 ✅ Screening: LD-CT for heavy smokers (55–74y) ✅ Biomarkers: EGFR, ALK & PD-L1 testing essential ✅ Surgery: Sublobar resection ≈ lobectomy for ≤2cm tumors

🌟🧠 #MWThinkWednesday Geriatric Assessment: ASCO Global Guideline 🌟 ✅ GA is recommended for all adults ≥65 receiving cancer treatment ✨ Identifies vulnerabilities beyond chronological age (function, comorbidities, polypharmacy, nutrition, cognition, psychosocial health)

🧠 #MWThinkWednesday Inferior control arms in oncology trials in LMICs: contextualised or compromised? ✅ Some oncology trials in LMICs still use inferior control arms vs HIC standards. ✅ Raises ethical concerns: are we contextualizing care or compromising patients?

💡 #MWClinicalTips Brain imaging screening in metastatic breast cancer: patients’ & physicians’ perspectives ✅ 529 physicians (50 countries): 65% request BIS in asymptomatic MBC, mainly for HER2+ & TNBC

🌍 #MWGlobalOnc Artificial intelligence across the cancer care continuum ✅ AI transforms oncology from prevention → survivorship → end-of-life care ✨ Early detection: deep learning predicts pancreatic & lung cancer risk yrs before diagnosis

🌟🚀 Novel trial designs in the era of molecular oncology🌟 🔑 Key insights: ✅ Molecular reclassification is reshaping cancer trial paradigms ✅ Basket & umbrella designs accelerate drug development across tumor types ✅ Adaptive, platform & seamless trials enable faster, more efficient testing

🧬 New AML care update for unfit patients Ven + HMA = current backbone ⚡️ CR/CRi ~40–90%, 3-yr OS up to 67% 📈 (better w/ NPM1, IDH2; worse w/ TP53, FLT3-ITD) Future: refine triplets ➕ optimize dosing, ASCT timing, & add PROs 🗣️ www.nature.com/articles/s41...

💡 #MWClinicalTips 📢 Advances in Neuroendocrine Tumors (NETs) — therapeutic landscape update ✅ NETs are highly heterogeneous — site of origin & biology determine management. ✅ Somatostatin analogs remain backbone for symptom & tumor control.

💡 #MWClinicalTips 📢 IMvigor011 trial: ctDNA-guided adjuvant immunotherapy in MIBC. Natera & Genentech/Roche ✅ Signatera-positive pts + atezolizumab → significant ↑ DFS & OS ✅ Signatera-negative pts → excellent outcomes w/out adjuvant Rx

🌍 #MWGlobalOnc ✨ Treatment of NSCLC after chemoimmunotherapy — are we making headway? ✅ Most NSCLC pts eventually develop resistance to ICIs (primary 5–20%, secondary 60–85%). ✨ Resistance mechanisms converge into an immunosuppressive TME.

💡 #MWPaperFriday ✨ Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in metastatic breast cancer ✅ Real-world data from 793 pts receiving post-T-DXd therapy (12/2019–09/2023) ➡️ Median rwPFS by subtype:  • HER2+: 4.6 mo (best with endocrine tx: 6.7 mo; worst with

💡 #MWPaperFriday ✨ Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in metastatic breast cancer ✅ Real-world data from 793 pts receiving post-T-DXd therapy (12/2019–09/2023) ➡️ Median rwPFS by subtype:  • HER2+: 4.6 mo (best with endocrine tx: 6.7 mo; worst with

🌍 #MWGlobalOnc Hormonal factors predictive of fertility in breast cancer — POSITIVE trial ✅ Baseline AMH predicts likelihood of pregnancy after pausing adjuvant endocrine therapy. ✅ Higher AMH + younger age → higher conception rates. ✨ 73% with high AMH achieved pregnancy vs. 33% with low AMH.

🌍 #MWGlobalOnc Hormonal factors predictive of fertility in breast cancer — POSITIVE trial ✅ Baseline AMH predicts likelihood of pregnancy after pausing adjuvant endocrine therapy. ✅ Higher AMH + younger age → higher conception rates. ✨ 73% with high AMH achieved pregnancy vs. 33% with low AMH.

Now online in Cancer Discovery @aacrjournals.bsky.social: Integrative Proteogenomics & Forward Genetics Reveals a Novel Mitotic Vulnerability in TNBC - by Nicholas Neill, Shankha Satpathy, Trey Westbrook and colleagues doi.org/10.1158/2159... @bcmfromthelabs.bsky.social @broadinstitute.org

Recent data in #NSCLC point to advances in molecular testing, targeted therapy and predictive modeling. These updates may influence diagnostic workflows, therapeutic selection and clinical trial design. Here are 3 updates every thoracic oncologist should know 🧵⬇️

Read of the Week, in @cancerletter.com by Dr. Lou Weiner @medstarhealth.bsky.social @rueschcenter.bsky.social: cancerletter.com/guest-editor... #Holocaust #history #medicine #oncology

The numbers of women in science falls substantially at the transition from postdoc to independent investigator/ PI So what can we do to prevent this? One initiative we now organise annually at #EACR is the highly successful 'Women in Leadership' workshop ⏬ #WomenInScience 🧪 @helloeacr.bsky.social

🚨 @fda.gov Approval Alert Perioperative #KEYTRUDA® (pembrolizumab) + #PADCEV® (enfortumab vedotin-ejfv) receives FDA approval for cisplatin-ineligible MIBC before & after surgery.

🚨 Big developments in breast cancer care From AI-driven diagnostics to prevention strategies and novel targeted therapies, new research is shaping how we detect, prevent and treat disease. Here are 3 updates every oncologist should know 🧵⬇️

🌟💡 #MWClinicalTips ✨ Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic & colorectal cancer: phase 1 AMPLIFY-201 trial final results ✅ mKRAS-specific amphiphile vaccines drive robust CD4+ & CD8+ T cell responses in pancreatic & colorectal cancer.

🩸 MRD status is reshaping #MultipleMyeloma care. MIDAS phase 3 trial shows: MRD-guided consolidation can personalize therapy after quadruple induction (isatuximab, carfilzomib, lenalidomide, dexamethasone) More aggressive ≠ always better outcomes MRD could help balance efficacy, toxicity & QoL

📚 #MWPaperMonday #PallOnc study in @jpsmjournal.bsky.social 🌟15 years after Temel’s landmark trial set early #pallonc as #SoC… only 8% of 🇺🇸 pts with metastatic cancer receive early specialist PC (≤8 wks from dx)

Dedifferentiated liposarcoma showing myxofibrosarcoma-like histology, H/T: @folpe-mn-st.bsky.social

Expansion of tumor-reactive CD8+ T cell clonotypes, H/T @eunusali.bsky.social

New avenue of research in prevention of gastric cancer, H/T: @weldeiry.bsky.social

Stem cell therapy side effects, H/T: @bllphd.bsky.social

GSK and Oxford to collaborate on cancer research, H/T: @pjmcg.bsky.social

KRAS-G12D–targeted therapy in advanced pancreatic cancer, H/T: @lgoodbu.bsky.social

Massive localized lymphedema, H/T: @folpe-mn-st.bsky.social

Pamrevlumab + chemo fails to improve OS and PFS in locally advanced pancreatic cancer, H/T: @lgoodbu.bsky.social

Angiomatoid fibrous histiocytoma, H/T: @folpe-mn-st.bsky.social

Dr Spira on RMC-9805 in KRAS G12D–Mutated Pancreatic Ductal Adenocarcinoma - goo.gl/alerts/8GPfj9 #GoogleAlerts